Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to ...

The Chart of the Day What we're watching What we're reading Economic data releases and earnings After the Pelotons (PTON) and Zooms (ZM) of the world enjoyed their glorious time in the pandemic sun, ...

Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

A new weight loss plan that embraces real food, flexibility and freedom is climbing Amazon’s bestseller charts - overtaking ...

A new weight loss plan that embraces real food, flexibility and freedom is climbing Amazon’s bestseller charts - just days after it was featured in the UK’s most-read women’s magazine, Fabulous.

Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...

Hers reports 12% of Americans feel judged by doctors for their weight, highlighting significant weight bias in healthcare and ...

People on weight-loss drugs often lose muscle mass while they lose weight, but new scientific findings suggest boosting your ...

Dozens of lawmakers are urging U.S. health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...